{"id":176,"date":"2008-09-04T23:13:03","date_gmt":"2008-09-04T14:13:03","guid":{"rendered":"http:\/\/haruko.km2m.net\/2008\/09\/04\/r-chop%e7%99%82%e6%b3%95%e5%be%8c%e3%81%ae%e3%82%bc%e3%83%b4%e3%82%a1%e3%83%aa%e3%83%b3\/"},"modified":"2008-09-04T23:13:03","modified_gmt":"2008-09-04T14:13:03","slug":"r-chop%e7%99%82%e6%b3%95%e5%be%8c%e3%81%ae%e3%82%bc%e3%83%b4%e3%82%a1%e3%83%aa%e3%83%b3","status":"publish","type":"post","link":"https:\/\/haruko.km2m.net\/?p=176","title":{"rendered":"R-CHOP\u7642\u6cd5\u5f8c\u306e\u30bc\u30f4\u30a1\u30ea\u30f3"},"content":{"rendered":"<p>\u672a\u6cbb\u7642\u306e\u6ffe\u80de\u6027NHL\u60a3\u8005\u306b\u5bfe\u3057\u3066\u6709\u671b\u306aR-CHOP\u7642\u6cd5\u5f8c\u306e\u30bc\u30f4\u30a1\u30ea\u30f3&reg;[Zevalin]\/\u30ea\u30c4\u30ad\u30b5\u30f3&reg;[Rituxan]\u4f75\u7528\u6295\u4e0e2006\/6<\/p>\n<p>\u539f\u6587<br \/>\n\u672a\u6cbb\u7642\u306e\u6ffe\u80de\u6027NHL\u60a3\u8005\u306b\u5bfe\u3057\u3066\u6709\u671b\u306aR-CHOP\u7642\u6cd5\u5f8c\u306e\u30bc\u30f4\u30a1\u30ea\u30f3&reg;[Zevalin]\/\u30ea\u30c4\u30ad\u30b5\u30f3&reg;[Rituxan]\u4f75\u7528\u6295\u4e0e <br \/>\nCancerConsultants\u30002006\/6\/21<\/p>\n<p>\n\u7b2c2\u76f8\u8a66\u9a13\u306e\u7d50\u679c\u3001\u6ffe\u80de\u6027\u975e\u30db\u30b8\u30ad\u30f3\u30ea\u30f3\u30d1\u816b(NHL)\u306e\u521d\u671f\u6cbb\u7642\u3068\u3057\u3066\u3001R-CHOP\u7642\u6cd5\uff08C\uff1a\u30b7\u30af\u30ed\u30d5\u30a9\u30b9\u30d5\u30a1\u30df\u30c9\uff08\u30a8\u30f3\u30c9\u30ad\u30b5\u30f3\uff09\u3001H\uff1a\u30a2\u30c9\u30ea\u30a2\u30de\u30a4\u30b7\u30f3\uff08\u30a2\u30c9\u30ea\u30a2\u30b7\u30f3\uff09\u3001O\uff1a\u30d3\u30f3\u30af\u30ea\u30b9\u30c1\u30f3\uff08\u30aa\u30f3\u30b3\u30d3\u30f3\uff09\u3001P\uff1a\u30d7\u30ec\u30c9\u30cb\u30f3\uff0bR:\u30ea\u30c4\u30ad\u30b5\u30f3\uff08\u30ea\u30c4\u30ad\u30b7\u30de\u30d6\uff09\uff09\u5f8c\u306e\u30bc\u30f4\u30a1\u30ea\u30f3(90Y ibritumomab tiuxetan)\u304a\u3088\u3073\u30ea\u30c4\u30ad\u30b5\u30f3(\u30ea\u30c4\u30ad\u30b7\u30de\u30d6)\u306e\u4f75\u7528\u6295\u4e0e\u304c\u3001\u9ad8\u3044\u5b8c\u5168\u5bdb\u89e3\u7387\u3092\u3082\u305f\u3089\u3057\u3001\u75be\u60a3\u306e\u7121\u9032\u884c\u751f\u5b58\u7387\u3092\u6539\u5584\u3059\u308b\u3053\u3068\u304c\u5831\u544a\u3055\u308c\u305f\u3002\u3053\u308c\u3089\u306e\u7d50\u679c\u306f\u3001\u7b2c42\u56de\u7c73\u56fd\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a(ASCO)\u306e\u5e74\u6b21\u7dcf\u4f1a\u306b\u304a\u3044\u3066\u767a\u8868\u3055\u308c\u305f\u3002<\/p>\n<p>\u75be\u60a3\u306e\u69d8\u3005\u306a\u9032\u884c\u6bb5\u968e\u3067\u3001\u30bc\u30f4\u30a1\u30ea\u30f3\u3092\u8a55\u4fa1\u3059\u308b\u8a66\u9a13\u304c\u3001\u521d\u671f\u6cbb\u7642\u3082\u542b\u3081\u3001\u5b9f\u65bd\u3055\u308c\u3066\u3044\u308b\u3002\u5148\u306e\u8a66\u9a13\u3067\u3001\u6ffe\u80de\u6027NHL\u306e\u521d\u671f\u6cbb\u7642\u3068\u3057\u3066\u306e\u3001\u30bc\u30f4\u30a1\u30ea\u30f3\u6295\u4e0e\u304a\u3088\u3073R-CHOP\u7642\u6cd5\u3068\u306e\u7d44\u307f\u5408\u308f\u305b\u304c\u3001\u6709\u671b\u306a\u7d50\u679c\u3092\u793a\u3057\u3001\u8fd1\u3054\u308d\u30d4\u30c3\u30c4\u30d0\u30fc\u30b0\u5927\u5b66(University of Pittsburg)\u306e\u533b\u5e2b\u3089\u304c\u3001\u672c\u6cbb\u7642\u65b9\u6cd5\u306e\u66f4\u306a\u308b\u8a55\u4fa1\u306e\u305f\u3081\u3001\u7b2c2\u76f8\u5358\u4e00\u65bd\u8a2d\u8a66\u9a13\u3092\u5b9f\u65bd\u3057\u305f\u3002\u8a66\u9a13\u306b\u306f30\u4eba\u306e\u8a55\u4fa1\u53ef\u80fd\u306a\u3001\u30b0\u30ec\u30fc\u30c91~3\u3001\u307e\u305f\u306f\u30b9\u30c6\u30fc\u30b8\u2161\uff5e\u2163\u306e\uff08\u3042\u308b\u3044\u306f\u30b9\u30c6\u30fc\u30b8\u2160\uff0d\u2161\u3067\u3042\u308c\u3070\u3001\u75c7\u72b6\u306e\u3042\u308b\uff09CD20\u967d\u6027\u6ffe\u80de\u6027NHL\u60a3\u8005\u304c\u767b\u9332\u3057\u305f\u3002\u60a3\u8005\u306f\u3001\u5316\u5b66\u7642\u6cd5\u3084\u30e2\u30ce\u30af\u30ed\u30ca\u30eb\u6297\u4f53\u306b\u3088\u308b\u524d\u6cbb\u7642\u3092\u53d7\u3051\u3066\u304a\u3089\u305a\u3001\u305d\u306e\u534a\u6570\u306f\u3001\u30b9\u30c6\u30fc\u30b8\u2163\u306b\u75be\u60a3\u304c\u9032\u884c\u3057\u3066\u3044\u305f\u3002\u8a66\u9a13\u306e\u6cbb\u7642\u6cd5\u306f\u4ee5\u4e0b\u306e\u901a\u308a\u3067\u3042\u308b\u3002<\/p>\n<p>\u30fb3\u30b5\u30a4\u30af\u30eb\u306e\u6a19\u6e96R-CHOP\u7642\u6cd5\u3002<br \/>\n\u30fbR-CHOP\u7642\u6cd5\u306e\u6700\u7d42\u6295\u4e0e\u306e4\u9031\u9593\u5f8c\u306b\u3001\u30bc\u30f4\u30a1\u30ea\u30f3\u306b\u3088\u308b\u6cbb\u7642\u3092\u53d7\u3051\u308b\u3002<br \/>\n\u30fb\u30bc\u30f4\u30a1\u30ea\u30f3\u306b\u3088\u308b\u6cbb\u7642\u306e1\u9031\u9593\u5f8c\u3088\u308a\u3001\u30ea\u30c4\u30ad\u30b5\u30f3(375 mg\/m2\u3092\u9759\u8108\u5185\u6295\u4e0e)\u306b\u3088\u308b\u6cbb\u7642\u30921\u9031\u9593\u306b1\u5ea6\u30014\u56de\u53d7\u3051\u308b\u3002<\/p>\n<p>\u4ee5\u4e0a\u306e\u6cbb\u7642\u3088\u308a\u3001\u4ee5\u4e0b\u306e\u7d50\u679c\u304c\u5831\u544a\u3055\u308c\u305f\u3002<\/p>\n<p>\u30fb\u30b3\u30f3\u30d4\u30e5\u30fc\u30bf\u65ad\u5c64\u64ae\u5f71\u6cd5(CT)\u30b9\u30ad\u30e3\u30f3\u306b\u57fa\u3065\u304fInternational Working Group\uff08IWG\uff09\u57fa\u6e96\u304a\u3088\u3073\u653e\u5c04\u65ad\u5c64\u64ae\u5f71\u6cd5(PET)\u30b9\u30ad\u30e3\u30f3\u306e\u7d50\u679c\u3092\u7528\u3044\u305f\u3001\u5b8c\u5168\u5bdb\u89e3\u7387\u304c\u3001R-CHOP\u7642\u6cd5\u5f8c\u306e35.7%\u304b\u3089\u3001\u30bc\u30f4\u30a1\u30ea\u30f3\u304a\u3088\u3073\u30ea\u30c4\u30ad\u30b5\u30f3\u306b\u3088\u308b\u6cbb\u7642\u5f8c\u306b\u306f89.3%\u306b\u5f15\u304d\u4e0a\u3052\u3089\u308c\u305f\u3002<br \/>\n\u30fb20\u30f6\u6708\u5f8c\u3001\u7121\u9032\u884c\u751f\u5b58\u7387\u306e\u4e2d\u592e\u5024\u306f\u7d0480\uff05\u3067\u3042\u3063\u305f\u3002<br \/>\n\u30fbR-CHOP\u7642\u6cd5\u306b\u653e\u5c04\u514d\u75ab\u7642\u6cd5(RIT)\u3092\u52a0\u3048\u308b\u3053\u3068\u3067\u3001\u30b0\u30ec\u30fc\u30c9\u2162\uff5e\u2163\u306e\u8840\u5c0f\u677f\u6e1b\u5c11\u75c7\u306e\u767a\u75c7\u983b\u5ea6\u304c\u3001R-CHOP\u7642\u6cd5\u4e2d\u306e3.3%\u304b\u3089\u3001RIT\u7642\u6cd5\u5f8c\u306e43%\u306b\u9ad8\u307e\u3063\u305f\u3002<br \/>\n\u30fb\u30b0\u30ec\u30fc\u30c9\u2162\uff5e\u2163\u306e\u597d\u4e2d\u7403\u6e1b\u5c11\u75c7\u304a\u3088\u3073\u767a\u71b1\u6027\u597d\u4e2d\u7403\u6e1b\u5c11\u75c7\u306e\u767a\u75c7\u983b\u5ea6\u306f\u3001RIT\u7642\u6cd5\u5f8c\u3088\u308aR-CHOP\u7642\u6cd5\u4e2d\u306e\u65b9\u304c\u9ad8\u304b\u3063\u305f\u3002<br \/>\n\u30fb\u30bc\u30f4\u30a1\u30ea\u30f3\u7642\u6cd5\u306e\u753b\u50cf\u5316\u306e\u6bb5\u968e\u306b\u304a\u3051\u308b\u3001\u816b\u760d\u306e\u30a4\u30f3\u30b8\u30a6\u30e0-111(indium-111)\u5438\u53ce\u304c\u3001\u5b8c\u5168\u5bdb\u89e3\u7387\u306e\u4f4e\u4e0b\u3068\u76f8\u95a2\u3057\u3066\u3044\u305f\u3002<br \/>\n\u30fb\u30d5\u30e5\u30fc\u30b8\u30e7\u30f3PET-CT\u30b9\u30ad\u30e3\u30f3\u306b\u3088\u308b\u6a5f\u80fd\u7684\u753b\u50cf\u5316\u306e\u65b9\u304c\u3001CT\u30b9\u30ad\u30e3\u30f3\u5358\u72ec\u3088\u308a\u3082\u3001\u6b8b\u5b58\u75c5\u5909\u306e\u691c\u77e5\u306b\u304a\u3044\u3066\u3001\u6b63\u78ba\u3067\u3042\u308b\u3053\u3068\u304c\u5206\u304b\u3063\u305f\u3002<\/p>\n<p>\u533b\u5e2b\u3089\u306f\u3001R-CHOP\u7642\u6cd5\u306b\u30bc\u30f4\u30a1\u30ea\u30f3\u304a\u3088\u3073\u30ea\u30c4\u30ad\u30b5\u30f3\u6295\u4e0e\u3092\u52a0\u3048\u308b\u3053\u3068\u306b\u3088\u308a\u3001\u672a\u6cbb\u7642\u306e\u6ffe\u80de\u6027NHL\u60a3\u8005\u306b\u5bfe\u3057\u3066\u3001\u6709\u671b\u306a\u5b8c\u5168\u5bdb\u89e3\u7387\u304a\u3088\u3073\u7121\u9032\u884c\u751f\u5b58\u7387\u306e\u6539\u5584\u3092\u3082\u305f\u3089\u3059\u3068\u7d50\u8ad6\u4ed8\u3051\u305f\u3002\u307e\u305f\u533b\u5e2b\u3089\u306f\u3001\u672c\u6cbb\u7642\u6cd5\u306e\u6709\u52b9\u6027\u3092\u672c\u5f53\u306b\u8a55\u4fa1\u3059\u308b\u306b\u306f\u3001\u9577\u671f\u306e\u30d5\u30a9\u30ed\u30fc\u30a2\u30c3\u30d7\u304c\u5fc5\u8981\u3067\u3042\u308b\u3068\u6ce8\u610f\u3092\u4fc3\u3057\u3066\u3044\u308b\u3002<\/p>\n<p>Reference: DeMonaco N, Wu M, Osborn J, et al. Phase 2 Trial of CHOP-Rituximab Followed by 90Y ibritumomab Tiuxetan (Zevalin) and Rituximab in Patients with Previously Untreated Follicular Non-Hodgkin Lymphoma. Proceedings from the 42nd annual meeting of the American Society of Clinical Oncology (ASCO). Atlanta, Ga. June 2006. Abstract #7589.<\/p>\n<p>****** <\/p>\n<p>(Oonishi\u3000\u8a33\u30fbDr.Saru\u3000\u76e3\u4fee\uff09 <\/p>\n<p>http:\/\/www.cancerit.jp\/reference\/diary.cgi?no=52<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u672a\u6cbb\u7642\u306e\u6ffe\u80de\u6027NHL\u60a3\u8005\u306b\u5bfe\u3057\u3066\u6709\u671b\u306aR-CHOP\u7642\u6cd5\u5f8c\u306e\u30bc\u30f4\u30a1\u30ea\u30f3&reg;[Zevalin]\/\u30ea\u30c4\u30ad\u30b5\u30f3&reg;[Rituxan]\u4f75\u7528\u6295\u4e0e2006\/6 \u539f\u6587 \u672a\u6cbb\u7642\u306e\u6ffe\u80de\u6027NHL\u60a3\u8005\u306b\u5bfe\u3057\u3066\u6709\u671b\u306aR-CHOP\u7642\u6cd5\u5f8c &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/haruko.km2m.net\/?p=176\" class=\"more-link\"><span class=\"screen-reader-text\">&#8220;R-CHOP\u7642\u6cd5\u5f8c\u306e\u30bc\u30f4\u30a1\u30ea\u30f3&#8221; \u306e<\/span>\u7d9a\u304d\u3092\u8aad\u3080<\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-176","post","type-post","status-publish","format-standard","hentry","category-4"],"_links":{"self":[{"href":"https:\/\/haruko.km2m.net\/index.php?rest_route=\/wp\/v2\/posts\/176","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haruko.km2m.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haruko.km2m.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haruko.km2m.net\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/haruko.km2m.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=176"}],"version-history":[{"count":0,"href":"https:\/\/haruko.km2m.net\/index.php?rest_route=\/wp\/v2\/posts\/176\/revisions"}],"wp:attachment":[{"href":"https:\/\/haruko.km2m.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=176"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haruko.km2m.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=176"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haruko.km2m.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=176"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}